Rhythm Company Profile
✉ Email this page to a colleague
What is the competitive landscape for RHYTHM
RHYTHM has one approved drug.
There are three US patents protecting RHYTHM drugs.
Summary for Rhythm
| US Patents: | 3 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Rhythm
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rhythm | IMCIVREE | setmelanotide acetate | SOLUTION;SUBCUTANEOUS | 213793-001 | Nov 25, 2020 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Rhythm | IMCIVREE | setmelanotide acetate | SOLUTION;SUBCUTANEOUS | 213793-001 | Nov 25, 2020 | RX | Yes | Yes | 11,129,869 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Rhythm | IMCIVREE | setmelanotide acetate | SOLUTION;SUBCUTANEOUS | 213793-001 | Nov 25, 2020 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Rhythm | IMCIVREE | setmelanotide acetate | SOLUTION;SUBCUTANEOUS | 213793-001 | Nov 25, 2020 | RX | Yes | Yes | 8,039,435 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Rhythm | IMCIVREE | setmelanotide acetate | SOLUTION;SUBCUTANEOUS | 213793-001 | Nov 25, 2020 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Rhythm Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 102378943 | ⤷ Start Trial |
| Canada | 3209602 | ⤷ Start Trial |
| European Patent Office | 2286825 | ⤷ Start Trial |
| Spain | 2604328 | ⤷ Start Trial |
| Israel | 201732 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Rhythm Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2236151 | 21C1060 | France | ⤷ Start Trial | PRODUCT NAME: SETMELANOTIDE OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/21/1564 20210719 |
| 2970389 | 2021C/551 | Belgium | ⤷ Start Trial | PRODUCT NAME: SETMELANOTIDE, ALSMEDE DOOR HET BASISOCTROOI BESCHERMDE, THERAPEUTISCH EQUIVALENTE AFGELEIDEN ERVAN; AUTHORISATION NUMBER AND DATE: EU/1/21/1564 20210719 |
| 2970389 | 21C1059 | France | ⤷ Start Trial | PRODUCT NAME: SETMELANOTIDE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/21/1564 20210719 |
| 2236151 | 301150 | Netherlands | ⤷ Start Trial | PRODUCT NAME: SETMELANOTIDE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/21/1564 20210719 |
| 2970389 | C202130071 | Spain | ⤷ Start Trial | PRODUCT NAME: IMCIVREE-SETMELANOTIDA; NATIONAL AUTHORISATION NUMBER: EU/1/21/1564; DATE OF AUTHORISATION: 20210716; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/21/1564; DATE OF FIRST AUTHORISATION IN EEA: 20210716 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
